Related Experiment Video
Updated: May 10, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
miR-124 radiosensitizes human glioma cells by targeting CDK4
Xubin Deng1, Lei Ma, Minhua Wu
1Cancer Institute of Southern Medical University, Guangzhou, People's Republic of China.
Abstract:
The aberrant expression of cyclin-dependent kinase-4 (CDK4) has previously been observed in human brain glioma. Furthermore, it is observed that up-regulation of CDK4 is associated with therapy resistance and relapse. However, the mechanisms behind these phenomena remain unclear. Here, we demonstrated that elevated CDK4 expression is correlated with poor prognosis in glioma after radiotherapy and that CDK4 knockdown conferred radiosensitivity in glioma cell lines. CDK4 was identified as potential downstream target of miR-124 through bioinformatics analysis and dual-firefly luciferase reporter assay. Furthermore, restoration of miR-124 could confer radiosensitivity. Cell differentiation agent-2 (CDA-2) mimicked the effect of miR-124 restoration and CDK4 knockdown, and sensitized xenografts to radiation in an animal model. Our findings demonstrated for the first time that CDK4 was a downstream target of miR-124 and that CDA-2 could radiosensitize Glioblastoma multiforme cells through the MiR-124-CDK4 axis.
Insights
Elevated cyclin-dependent kinase-4 (CDK4) expression in glioma correlates with poor prognosis and therapy resistance. Restoring miR-124 or using CDA-2 sensitizes glioblastoma cells to radiation by targeting CDK4.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrant cyclin-dependent kinase-4 (CDK4) expression is linked to human brain glioma, therapy resistance, and relapse.
- The precise mechanisms underlying CDK4's role in glioma progression and treatment failure remain largely undefined.
Purpose of the Study:
- To investigate the correlation between elevated CDK4 expression and glioma prognosis post-radiotherapy.
- To elucidate the regulatory relationship between miR-124 and CDK4 in glioma.
- To evaluate the radiosensitizing potential of cell differentiation agent-2 (CDA-2) in glioblastoma.
Main Methods:
- Bioinformatics analysis and dual-firefly luciferase reporter assays were employed to identify CDK4 as a downstream target of miR-124.
- CDK4 knockdown and miR-124 restoration were performed in glioma cell lines.
- A xenograft animal model was used to assess the efficacy of CDA-2 in sensitizing tumors to radiation.
Main Results:
- Elevated CDK4 expression was significantly correlated with poor prognosis in glioma patients following radiotherapy.
- CDK4 knockdown and miR-124 restoration both conferred radiosensitivity to glioma cell lines.
- CDA-2 effectively mimicked the effects of miR-124 restoration and CDK4 knockdown, sensitizing xenografts to radiation.
Conclusions:
- CDK4 is identified as a direct downstream target of miR-124 in the context of glioma.
- The miR-124-CDK4 axis plays a crucial role in regulating glioma radiosensitivity.
- CDA-2 demonstrates potential as a therapeutic agent to enhance glioblastoma radiosensitization via the miR-124-CDK4 pathway.